Follow us on or join ours

The small capital company Agenus Inc. intends to raise $ 50 million to $ 100 million by issuing digital assets backed by planned sales of an experimental anti-cancer drug. This is a completely innovative approach when it comes to the biotechnology industry.

Agenus and innovative biotechnology security tokens

As the company promises, digital assets will enable investment in the future sale of individual products, while exerting limited influence on shareholders. The company intends to offer its innovative, biotechnology security tokens (referred to by the company as BESTs) with a value of at least 25 million dollars. General manager of the company, Garo Armen, he argues that thanks to this type of innovative solutions, it is possible to submit a presentation much more focused on a specific product.

American company Agenus concentrating on immuno-oncological treatment, and is currently conducting clinical trials of the drug for cervical cancer, which can be approved already in the 2021 year. The digital offer, however, carries a certain degree of risk. First, to start generating income, the drug must be approved by securities regulators. Although the company's representatives ensure that the offer complies with the regulations of the Securities and Exchange Commission of the United States (SEC), it has not been finally approved by the Commission. This, according to Armen, takes place within a few months.

According to experts, the offer will help accelerate the development of an anti-cancer drug, although it may prove slightly dilutive for the shareholders themselves. At the same time, the management of Agenus ensures that the BESTs offer has nothing to do with cryptocurrencies, and the company does not currently participate in the cryptography market. Moreover, the company plans to take appropriate measures to protect investors if the drug is not allowed to circulate.

tokens companies are based on technology blockchain enabling verification and registration of transactions. Agenus acquires funds through a digital investment group Atomic Capital. Group representatives say that more and more biotechnology companies are turning towards digital financial methods.

4.7 / 5 - (4 votes) is a cryptocurrency site run by a crypto team of enthusiasts. The main area of ​​our interest are cryptocurrencies, tokens, personal tokens as well as blockchain technology. On the pages of our website we will present independent cryptocurrency reviews and interesting articles from the market. In addition, we present the current rates of all critics. The site also has a multi-functional cryptocurrency calculator as well as traditional currencies.

The information published on the cryptocurrency website are not financial recommendations and do not constitute investment recommendations within the meaning of the Regulation of the Minister of Finance of 19 October 2005 on information being recommendations regarding financial instruments, their issuers or issuers (Journal of Laws of 2005, No. 206, item 1715). The information published on the pages of the portal does not constitute an offer. is not responsible for any decisions taken under the influence of data presented on the Website. Portal does not bear any responsibility for the possible use of information on the website.

Investments in OTC market instruments, including currency exchange rate (CFD) contracts, due to the use of the leverage mechanism, entail the possibility of incurring losses exceeding the value of the deposit. It is not possible to make a profit on transactions on OTC instruments, including currency exchange contracts (CFDs) without risking a loss, therefore contracts for exchange differences (CFDs) may not be suitable for all investors.

© Copyright 2019

My Newsletter

Sign Up For Updates & Newsletters